BeOne Medicines AG

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

A study comparing injection under the skin versus infusion into the vein of tislelizumab with chemotherapy for patients with advanced gastric or gastroesophageal junction cancer

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Safety Study of Sonrotoclax and Zanubrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Safety Study of Sonrotoclax and Zanubrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Study of BGB-11417 and Azacitidine for Patients with Myeloid Malignancies (AML, MDS, MDS/MPN)

Study on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma

Study on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Untreated Chronic Lymphocytic Leukemia

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Untreated Chronic Lymphocytic Leukemia

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia